Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lipocine (LPCN) Research & Development (2016 - 2025)

Historic Research & Development for Lipocine (LPCN) over the last 13 years, with Q3 2025 value amounting to $2.7 million.

  • Lipocine's Research & Development rose 7081.26% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year decrease of 1225.6%. This contributed to the annual value of $7.4 million for FY2024, which is 2774.87% down from last year.
  • As of Q3 2025, Lipocine's Research & Development stood at $2.7 million, which was up 7081.26% from $2.1 million recorded in Q2 2025.
  • Over the past 5 years, Lipocine's Research & Development peaked at $3.1 million during Q1 2023, and registered a low of $1.1 million during Q1 2025.
  • Moreover, its 5-year median value for Research & Development was $2.1 million (2022), whereas its average is $2.1 million.
  • Per our database at Business Quant, Lipocine's Research & Development skyrocketed by 9785.88% in 2022 and then plummeted by 6234.13% in 2025.
  • Over the past 5 years, Lipocine's Research & Development (Quarter) stood at $2.3 million in 2021, then fell by 25.88% to $1.7 million in 2022, then rose by 0.27% to $1.7 million in 2023, then tumbled by 35.95% to $1.1 million in 2024, then soared by 152.39% to $2.7 million in 2025.
  • Its Research & Development was $2.7 million in Q3 2025, compared to $2.1 million in Q2 2025 and $1.1 million in Q1 2025.